These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 31347924)

  • 21. Hybridoma technology: is it still useful?
    Moraes JZ; Hamaguchi B; Braggion C; Speciale ER; Cesar FBV; Soares GFDS; Osaki JH; Pereira TM; Aguiar RB
    Curr Res Immunol; 2021; 2():32-40. PubMed ID: 35492397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review).
    Lu J; Ding J; Liu Z; Chen T
    Int J Oncol; 2022 Feb; 60(2):. PubMed ID: 34981814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hybridoma technology; advancements, clinical significance, and future aspects.
    Mitra S; Tomar PC
    J Genet Eng Biotechnol; 2021 Oct; 19(1):159. PubMed ID: 34661773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A hybridoma-derived monoclonal antibody with high homology to the aberrant myeloma light chain.
    Pornnoppadol G; Zhang B; Desai AA; Berardi A; Remmer HA; Tessier PM; Greineder CF
    PLoS One; 2021; 16(10):e0252558. PubMed ID: 34634047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IEDDA: An Attractive Bioorthogonal Reaction for Biomedical Applications.
    Handula M; Chen KT; Seimbille Y
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AAPS Perspective on the EURL Recommendation on the use of Non-Animal-Derived Antibodies.
    Gorovits B; Hays A; Jani D; Jones C; King C; Lundequist A; Mora J; Partridge M; Pathania D; Ramaswamy SS; Rutwij D; Shen H; Starling G
    AAPS J; 2021 Mar; 23(2):34. PubMed ID: 33649990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Tiered Approach for Characterization to Ensure Quality, Reproducibility, and Long-Term Stability of Critical Reagents in Regulated Bioanalysis to Support PK/ADA/NAb Assays for Biologics and Vaccines Programs.
    Yang K; Zhang Y; Chou R; Yeung L; Letarte S; Yang RS; Li X; Beaumont M; Gunawan R; Richardson D; Dellatore S; Woolf E; Xu Y
    ACS Pharmacol Transl Sci; 2020 Dec; 3(6):1310-1317. PubMed ID: 33344904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The UK Veterinary Immunological Toolbox Website: promoting vaccine research by facilitating communication and removing reagent barriers.
    Mwangi W; Maccari G; Hope JC; Entrican G; Hammond JA
    Immunology; 2020 Sep; 161(1):25-27. PubMed ID: 32548865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives.
    Parray HA; Shukla S; Samal S; Shrivastava T; Ahmed S; Sharma C; Kumar R
    Int Immunopharmacol; 2020 Aug; 85():106639. PubMed ID: 32473573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibodies, Nanobodies, or Aptamers-Which Is Best for Deciphering the Proteomes of Non-Model Species?
    Dhar P; Samarasinghe RM; Shigdar S
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of monoclonal antibodies for the diagnosis and treatment of bladder cancer.
    Syrigos KN; Deonarian DP; Epenetos AA
    Hybridoma; 1999 Jun; 18(3):219-24. PubMed ID: 10475235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of monoclonal antibody immunoconjugates in cancer therapy.
    Pietersz GA; Krauer K; McKenzie IF
    Adv Exp Med Biol; 1994; 353():169-79. PubMed ID: 7985535
    [No Abstract]   [Full Text] [Related]  

  • 33. Hybridoma technology: the preferred method for monoclonal antibody generation for
    Zaroff S; Tan G
    Biotechniques; 2019 Sep; 67(3):90-92. PubMed ID: 31347924
    [No Abstract]   [Full Text] [Related]  

  • 34. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation of Murine Monoclonal Antibodies by Hybridoma Technology.
    Holzlöhner P; Hanack K
    J Vis Exp; 2017 Jan; (119):. PubMed ID: 28117810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antibodies as specific tumor therapy agents. Wishful thinking or reality?].
    Gramatzki M; Valerius T
    Internist (Berl); 1997 Nov; 38(11):1055-62. PubMed ID: 9453954
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.